Evaluation of cardiac resynchronization therapy in drug-resistant dilated-phase hypertrophic cardiomyopathy by means of Tc-99m sestamibi ECG-gated SPECT.
This case describes a 65-year-old male with drug-resistant heart failure. Cardiac resynchronization therapy was performed. We evaluated cardiac function with volume curve differentiation software (VCDiff) from QGS data with Tc-99m sestamibi. Left ventricular parameters during atrial-right ventricular pacing were left ventricular ejection fraction (LVEF) 30%, end-diastolic volume (EDV) 156 ml, end-systolic volume (ESV) 108 ml and peak filling rate 1.12 (EDV/sec). And during dual chamber pacing, those were LVEF 35%, EDV 145 ml and ESV 95 ml and PFR 1.58 (EDV/sec). And during atrial-left ventricular pacing, those were LVEF 36%, EDV 152 ml, ESV 97 ml and peak filling rate (PFR) 1.35 (EDV/sec). Cardiac resynchronization therapy may improve cardiac function as well as dyssynchrony, which could be evaluated non-invasively and accurately by ECG-gated SPECT.
Matsuo
Shinro
S
Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Tukinowa-cho, Seta, Otsu, Shiga 520-2192, Japan. smatsuo@belle.shiga-med.ac.jp
Sato
Yuichi
Y
Nakae
Ichiro
I
Masuda
Daisuke
D
Matsumoto
Naoya
N
Horie
Minoru
M
D000368:Aged; D002311:Cardiomyopathy, Dilated / Q000175:diagnosis / Q000473:pathology; D002312:Cardiomyopathy, Hypertrophic / Q000175:diagnosis* / Q000473:pathology; D004452:Echocardiography; D004562:Electrocardiography / Q000379:methods*; D015637:Gated Blood-Pool Imaging / Q000379:methods; D006333:Heart Failure / Q000628:therapy; D006801:Humans; D008297:Male; D009206:Myocardium / Q000378:metabolism; D013902:Radiography, Thoracic / Q000379:methods; D019275:Radiopharmaceuticals / Q000494:pharmacology; D017256:Technetium Tc 99m Sestamibi / Q000494:pharmacology*; D013997:Time Factors; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*
D019275:Radiopharmaceuticals; D017256:Technetium Tc 99m Sestamibi